| scholarly article | Q13442814 |
| P50 | author | Diana Giannarelli | Q44736865 |
| P2093 | author name string | M Zeuli | |
| T Gamucci | |||
| F Cognetti | |||
| A Gabriele | |||
| V Ferraresi | |||
| C Nardoni | |||
| M S Pino | |||
| P433 | issue | 9 | |
| P921 | main subject | colorectal cancer | Q188874 |
| capecitabine | Q420207 | ||
| oxaliplatin | Q422327 | ||
| P304 | page(s) | 1378-1382 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer | |
| P478 | volume | 14 |
| Q36614036 | A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer |
| Q33366181 | A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer |
| Q33998072 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer |
| Q36187034 | Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer |
| Q37821286 | Capecitabine for locally advanced and metastatic colorectal cancer: A review |
| Q46965894 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. |
| Q34639725 | Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials |
| Q46538590 | Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q36626785 | Current directions in chemotherapy for colorectal cancer |
| Q35812742 | Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice |
| Q46113172 | Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin |
| Q37270388 | Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q35741932 | New systemic frontline treatment for metastatic colorectal carcinoma |
| Q33363451 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer |
| Q43898732 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. |
| Q55691415 | Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. |
| Q24815800 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer |
| Q33916021 | Targeting cancers in the gastrointestinal tract: role of capecitabine |
| Q37815612 | Update on capecitabine alone and in combination regimens in colorectal cancer patients |
| Q33370632 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer |
| Q79769145 | [A review of chemotherapy for metastatic colon cancer] |
Search more.